EMEA-001864-PIP01-15-M07 - paediatric investigation plan

Lanadelumab (DX-2930)
PIPHuman

Key facts

Invented name
Takhzyro
Active Substance
Lanadelumab (DX-2930)
Therapeutic area
Other
Decision number
P/0214/2022
PIP number
EMEA-001864-PIP01-15-M07
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of hereditary angioedema attacks
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Takeda Pharmaceuticals International AG Ireland Branch

E-mail: medinfoemea@takeda.com
Tel: +44 (0) 3333 000181

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance procedure number
EMEA-C-001864-PIP01-15-M07
Compliance opinion date
Compliance outcome
Positive

Decision

Share this page